etanercept + etanercept + placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

May 1, 2011 → Apr 1, 2013

NCT ID

NCT01298531

About etanercept + etanercept + placebo

etanercept + etanercept + placebo is a approved stage product being developed by Pfizer for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01298531. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

5 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (5) Terminated (1) Active (15)

🔄Brodalumab + PlaceboKyowa KirinPhase 3

🔄Ixekizumab + PlaceboEli LillyPhase 3

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

✅AdalimumabAbbVieApproved

🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3

🔄adalimumab + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01298531	Approved	Completed	May 1, 2011	Apr 1, 2013	Axial Spondyloarthritis
NCT00858780	Approved	Completed	Jan 1, 2009	Jun 1, 2012	Rheumatoid Arthritis
NCT00245960	Approved	Completed	Dec 27, 2005	Mar 29, 2008	Psoriatic Arthritis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27